Scientists are reporting a possible explanation for the bone loss that can occur after long-term use of a medicine widely used to treat epilepsy, bipolar disorder, and other conditions. 05 August 2010
In May, it was announced that new research into stem cell reprogramming would reduce the need for animal testing; now, we are really beginning to see the benefits of this groundbreaking science. 28 July 2010
Rising levels of antidepressants in coastal waters could change sealife behaviour and potentially damage the food chain, according to a new study. 16 July 2010
Promega Corporation has partnered with SignalChem Pharmaceuticals to launch a complete kinase solution for the profiling of lead compounds against kinases representative of all major families of the kinome. 13 July 2010
Thuricin CD, an antibiotic licensed to Alimentary Health, has been found to be effective against the hospital-acquired superbug Clostridium difficile. 08 July 2010
Research funded by hearing loss charity RNID has discovered a drug that repairs hearing after damage caused by loud noise. 06 July 2010
Marinomed Biotechnologie has signed a licensing agreement with Boehringer Ingelheim to market Marinomed’s anti-viral nasal spray for treating the common cold in Europe (except Austria and UK), Russia and CIS, South America, parts of Asia, and Australia. 29 June 2010
Researchers have been awarded £1.8 million to examine whether the use of pesticides is hampering the cognitive functions of bees – and possibly hastening their demise. 22 June 2010
Clinical results from a Phase IIb study have shown that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo in improving overall sleep efficiency in patients with primary insomnia. 18 June 2010
Hearing loss charity, RNID, is travelling to Chicago to launch a special issue of Drug Discovery Today at BIO International, the world’s largest biotechnology conference. RNID will be exhibiting at booth number 4707 Produced in association with RNID and Fight for Sight, the publication highlights the exciting progress being made in developing treatments for hearing and vision loss. 23 April 2010
Scientists have made a major breakthrough in identifying new treatments for human African trypanosomiasis, a fatal disease that infects tens of thousands of Africans each year. 01 April 2010
Vantia Therapeutics announced recently that it had revealed the structure of oral small-molecule drug candidate VA111913, a potential new treatment for dysmenorrhoea, for the first time. 29 March 2010
Cellzome announces second major strategic drug discovery alliance with GlaxoSmithKline in inflammatory disease. 10 March 2010
BioFine Europe 2010 will take place from 30–31 March and features The Peptide Conference 2010, the Synthetic Biology in Pharma conference and the BioFine Europe Exhibition. 03 February 2010
Companies to collaborate on an exclusive basis on Alizé Pharma's unacylated ghrelin (AZP-01) program for the treatment of type II diabetes. 26 January 2010
Rexahn Pharmaceuticals announces that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117. 21 January 2010
Astex Therapeutics announced recently that AstraZeneca has selected a clinical candidate from the PKB inhibitor collaborative programme. 08 January 2010
Light Sciences Oncology is anticipating significant short-term progress in the company’s multi-front development of Aptocine™ (talaporfin sodium), a novel treatment for solid tumors and benign neoplasms, including BPH. 14 December 2009
The Cambridge Crystallographic Data Centre has proudly announced the archiving of the 500,000th small-molecule crystal structure to the Cambridge Structural Database. 10 December 2009
An antibiotic that binds to a well-established target in a novel and unexpected way could be the inspiration for designing new, more potent antibiotic drugs. 04 December 2009
Heptares Therapeutics Ltd has announced the grant of a core patent in the UK on its technology for generating stabilized GPCRs (StaRs) and a series of UK patents on specific StaRs and their use in drug screening (GB2456235, GB2456237, GB2456904 and GB2456236). 20 November 2009
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. 19 November 2009
One difficulty with fighting cancer cells is that they are similar in many respects to the body’s stem cells. By focusing on the differences between the two cell types, researchers have found a new way of tackling colon cancer. 17 November 2009
GlaxoSmithKline (GSK) has recently announced the final results from its four-year combination therapy with Avodart and tamsulosin (CombAT) study. 16 October 2009
Scientists have discovered why a group of cancer drugs are so effective in treating the disease. Although they have been used for many years to treat certain tumours, researchers didn't know how they worked until now. 14 October 2009
Data presented at the American Society of Retina Specialists Conference in New York. 12 October 2009
The antibiotic minocycline could revolutionize the treatment of strokes. 06 October 2009
Major new collaboration announced at Clinton Global Initiative Annual Meeting. 06 October 2009
Karus Therapeutics Ltd, a company developing small-molecule drugs to treat cancer and inflammation, announced recently that it has signed an agreement to collaborate with Professor Bart Vanhaesebroeck at Queen Mary, University of London. 29 September 2009
AstraZeneca and Nektar Therapeutics announced recently that they have entered into a worldwide license agreement for two drug development programmes: NKTR-118, a late-stage investigational product being evaluated for the treatment of opioid-induced constipation, and the NKTR-119 programme, an early-stage programme that is intended to deliver products for the treatment of pain without constipation side-effects. 24 September 2009
Further pain reduction on duloxetine shown during study’s extension phase. 14 September 2009
As the 20th Drug Delivery to the Lungs (DDL) conference approaches, DDL Chairman Sandy Munro offers his view on what he anticipates to be the highlights for this year’s conference; including the aims to maintain the Drug Delivery to the Lungs (DDL) technical focus while broadening its horizons. He will also be previewing what's in store for this year's special anniversary event. 09 September 2009
Forty years ago men landed on, and walked on, the moon. 20 August 2009
The European Commission has approved the Marketing Authorisation Application for Otsuka's oral once-daily medication Samsca™ (tolvaptan), a selective V2-vasopressin receptor antagonist, for the treatment of hyponatraemia secondary to SIADH in adults. 04 August 2009
Victoza®, the first once-daily human glucagon-like peptide-1 (GLP-1) analogue that regulates blood sugar in a glucose-dependent manner, is now available for people with type 2 diabetes in the UK. 31 July 2009
Scientists have developed a new drug that can reduce the growth of tumours in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics recently. 27 July 2009
Cancer Research Technology, Merck Serono, Cancer Research UK, Cardiff University and The Institute of Cancer Research are set to begin a new research collaboration that will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets. 27 July 2009
Prostate cancer has overtaken lung cancer to become the most common cancer in men, affecting more than 35,000 men every year in the UK. Now, new UK research has confirmed that the cancer drug abiraterone provides a significant benefit for up to two-thirds of men with advanced and aggressive prostate cancer, according to a study published recently in the Journal of Clinical Oncology. 27 July 2009
New data presented recently at the British Society for Allergy and Clinical Immunology (BSACI) annual meeting have demonstrated that a new tablet treatment, Grazax®, is the first tablet treatment to provide sustained disease control in patients with grass pollen rhinoconjunctivitis (hay fever) after the treatment period ended. 21 July 2009
Parkinson's disease is a degenerative brain disorder that is triggered by death or degeneration of nerve cells in a part of the brain called substantia nigra. This brain region is essential in maintaining normal movement, so when the cells start to die off, patients lose the ability to properly execute and control movements. 21 July 2009
Email Address
Password
Forgotten login?